LIF and cancer: BM-MSCs enhance angiogenesis by releasing soluble factors (VEGF, Leukemia inhibitory factor- LIF, Macrophage Inflammatory Protein 2-MIP2) and exosomes that induce VEGF expression in cancer cells by activating extracellular signal-regulated kinase1/2 (ERK1/2) pathway (55).